The Dawn of AI-Driven Precision in Heart Attack Prognosis
A groundbreaking collaboration between Duke-NUS Medical School and the National Heart Centre Singapore (NHCS) has introduced LGE-CMRnet, an innovative end-to-end deep learning framework that automates the assessment of myocardial scar and microvascular obstruction (MVO) using late gadolinium enhancement cardiovascular magnetic resonance (LGE CMR) imaging. This advancement promises to transform post-acute myocardial infarction (AMI) risk stratification by providing rapid, accurate prognostic insights previously limited by manual analysis.
Acute myocardial infarction, commonly known as a heart attack, remains a leading cause of mortality worldwide, claiming 23 lives daily in Singapore alone according to recent health ministry data. Traditional LGE CMR, the gold standard for visualizing myocardial scar tissue and MVO—key indicators of adverse outcomes—relies on labor-intensive manual segmentation, prone to variability and delays. LGE-CMRnet addresses these challenges head-on, processing images in mere 0.05 seconds with expert-level prognostic accuracy.
Understanding the Clinical Challenge: Scar and MVO in AMI
Myocardial scar forms when heart muscle tissue dies following an AMI due to prolonged ischemia, while MVO represents areas of microvascular injury preventing reperfusion. Both are strong predictors of major adverse cardiac events (MACE), including recurrent infarction, heart failure, and mortality. Quantifying their extent via LGE CMR involves identifying hyperenhanced regions on images after gadolinium contrast administration.
Step-by-step, the process traditionally requires: (1) localizing the left ventricle, (2) segmenting healthy myocardium, (3) delineating scar (persistent enhancement), and (4) isolating MVO (hypointense cores within scar). Inter-observer variability can exceed 20%, and analysis times span 20-30 minutes per patient, hindering routine use in busy clinics like NHCS, Singapore's national referral center for complex cardiac cases.
In Singapore, where cardiovascular disease accounts for over 30% of deaths and incidence is projected to surge 150% in Southeast Asia by 2050 per NUS studies, scalable tools are critical. Duke-NUS, Singapore's premier graduate medical school, and NHCS have long championed translational research to combat this burden.
LGE-CMRnet: Engineering an End-to-End Solution
Developed by a multidisciplinary team led by researchers from NHCS's Cardiovascular Systems Imaging and Artificial Intelligence (CVS.AI) core and Duke-NUS's Cardiovascular & Metabolic Disorders Programme, LGE-CMRnet integrates YOLOv8 for automated heart localization and nnU-Net for simultaneous segmentation of myocardium, scar, and MVO.
Trained on 3,874 LGE images from 567 AMI patients (409 internal, 158 external validation), the model leverages vast NHCS datasets, reflecting Singapore's multi-ethnic population. This end-to-end pipeline eliminates manual preprocessing, delivering outputs as percentages of left ventricular mass (%Scar, %MVO)—clinically intuitive metrics for prognosis.
Unmatched Accuracy and Speed: Benchmarking Against Experts
External validation yielded Dice similarity coefficients (DSC)—a measure of segmentation overlap—of 0.83±0.11 for scar and 0.88±0.11 for MVO, with volumetric correlations r=0.90 (scar) and r=0.98 (MVO) to expert tracings. Bland-Altman plots confirmed minimal bias (scar: 2.5±8.9 cm³; MVO: 0.20±0.89 cm³), positioning LGE-CMRnet as non-inferior for clinical deployment.
Processing at 0.05 seconds per image versus 20+ minutes manually scales effortlessly for high-volume centers like NHCS, which performs thousands of CMRs annually. This efficiency could reduce reporting backlogs, enabling same-day prognostication.
Prognostic Power: Predicting MACE with AI Precision
In the 158-patient external cohort (median follow-up 24.4 months), 22.2% suffered MACE. Cox regression revealed LGE-CMRnet-derived %MVO (HR 1.06, 95% CI 1.02-1.09, P=0.003) and %Scar (HR 1.05, 95% CI 1.02-1.08, P=0.001) as independent predictors, outperforming traditional models after adjusting for age, ejection fraction, and TIMI risk score.
C-index comparisons showed equivalence to experts (Δ0.02 for %MVO, Δ0.01 for %Scar), affirming reliability. The full study in JACC: Cardiovascular Imaging underscores AI's role in personalized post-AMI management.
Duke-NUS and NHCS: Pillars of Singapore's Biomedical Innovation
Duke-NUS Medical School, a National University of Singapore-Duke University partnership since 2005, excels in clinician-scientist training, producing leaders like principal investigators Derek Hausenloy and Liang Zhong. NHCS, Asia's largest heart center, hosts the CVS.AI lab, pioneering tools like SENSE for coronary artery disease detection—now trialed across SingHealth polyclinics.
Their synergy exemplifies Singapore's Biomedical Research Council vision, investing S$25 billion by 2030 in AI-health hubs like DAISI at Duke-NUS. This LGE-CMRnet work builds on prior feats, including AI-triage for chest pain and APOLLO imaging platforms.
Real-World Impact on Singapore's Healthcare Landscape
Singapore's ageing population (20% over 65 by 2030) faces rising AMI burdens, with ischaemic heart disease topping mortalities. LGE-CMRnet could integrate into NHCS workflows, aiding risk-tailored therapies like intensified statins for high %Scar patients or closer monitoring for MVO-dominant cases.
Stakeholders praise: NHCS Director Prof. Nicholas Chan notes "AI augments expertise, not replaces it"; Duke-NUS Dean Prof. Dean Ho highlights translational speed. Economically, reducing MACE by 10% could save S$100 million annually in HF admissions.
Challenges, Limitations, and Ethical Considerations
While robust, LGE-CMRnet requires diverse datasets to mitigate ethnic biases—Singapore's multi-ethnic validation helps. Limitations include dependency on LGE quality and generalizability beyond AMI. Regulatory hurdles via Singapore's Health Sciences Authority loom, demanding prospective trials.
- Pros: Speed, scalability, prognostic equivalence
- Cons: Training data needs, explainability gaps
- Risks: Over-reliance, data privacy
Singapore's AI governance framework ensures ethical deployment.
Singapore's AI Vanguard in Cardiovascular Research
Beyond LGE-CMRnet, Duke-NUS/NHCS advances include AI for HFpEF biomarkers and quantum-enhanced imaging. Nationally, A*STAR's PREVENT-AMI predicts events pre-symptomatically. NHCS CVS.AI fosters clinician-AI synergy, training fellows in deep learning.
Future Outlook: From Bench to Bedside
Prospective RCTs at NHCS will validate clinical utility, potentially FDA/CE-marking by 2028. Integration with wearables for dynamic prognostication looms, aligning with Singapore's Smart Nation 2.0. For higher ed, Duke-NUS expands AI curricula, preparing clinician-scientists.
Actionable insights: Clinicians adopt hybrid AI-manual workflows; researchers pursue multi-modal fusion (CMR+echo+ECG).
Photo by David Kubovsky on Unsplash
Career Pathways in Singapore's AI-Cardiology Frontier
Duke-NUS offers PhD fellowships in DAISI; NHCS recruits AI specialists via SingHealth. With 1,000+ biomedical jobs yearly, opportunities abound in research assistantships, postdocs, and faculty roles.
